Jun Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Guan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Xiaojun Chen
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
5 shared publications - Bingyi Yang
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
3 shared publications - Weiwei Shan
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
3 shared publications - Qin Zhu
Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
2 shared publications - Xuezhen Luo
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
2 shared publications - Zhiying Xu
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914)
Xu Z, et al. J Gynecol Oncol. 2022 Dec;34(1):e32. https://doi.org/10.3802/jgo.2023.34.e32
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Open AccessComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914)
Xu Z, et al. J Gynecol Oncol. 2022 Dec;34(1):e32. https://doi.org/10.3802/jgo.2023.34.e32
- Open Access
- 4 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (4) , 1135-1146
Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
Objective: Morular metaplasia (MM) is a benign epithelial metaplasia that sometimes appears in atypical endometrial hyperplasia (AEH) and endometrioid endometrial carcinoma (EEC). However, the clinical implications of MM for fertility-preserving treatment in AEH and EEC patients are unclear. This study investigated the clinical features and impact of MM on the efficacy of fertility-preserving treatment. Methods: We retrospectively studied 427 AEH and EEC patients who received fertility-preserving treatment. Clinical features, treatment efficacy, and onco-fertility results were compared between patients with and without MM. Results: MM appeared in 147 of 427 (34.4%) patients. Among them, 49 (33.3%) had MM only before treatment (BEF group), 32 (21.8%) had sustained MM before and during treatment (SUS group), and 66 (44.9%) had MM only during treatment (DUR group). The BEF group had a higher 12-month CR rate (98.0% vs 85.7%, p = 0.017) and shorter therapeutic duration to achieve CR (4.0 vs 5.7 months, p = 0.013) than the non-MM group had. In comparison with the non-MM group, the SUS and DUR groups had a lower CR rate after 7 months of treatment (SUS vs non-MM, 37.5% vs 61.1%, p = 0.010; DUR vs non-MM 33.3% vs. 61.1%, p < 0.001), and a longer median therapeutic duration to achieve CR (SUS vs non-MM, 7.6 vs. 4.0 months, p = 0.037; DUR vs non-MM, 7.9 vs. 4.0 months, p < 0.001). Conclusion: Appearance of MM only before treatment was positively correlated with outcome of fertility-preserving treatment, while sustained MM or appearance of MM only during treatment implied poorer outcome of fertility-preserving treatment in AEH and EEC patients.
- 4 March 2022
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 306 (4) , 1135-1146
Open AccessClinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
Objective: Morular metaplasia (MM) is a benign epithelial metaplasia that sometimes appears in atypical endometrial hyperplasia (AEH) and endometrioid endometrial carcinoma (EEC). However, the clinical implications of MM for fertility-preserving treatment in AEH and EEC patients are unclear. This study investigated the clinical features and impact of MM on the efficacy of fertility-preserving treatment. Methods: We retrospectively studied 427 AEH and EEC patients who received fertility-preserving treatment. Clinical features, treatment efficacy, and onco-fertility results were compared between patients with and without MM. Results: MM appeared in 147 of 427 (34.4%) patients. Among them, 49 (33.3%) had MM only before treatment (BEF group), 32 (21.8%) had sustained MM before and during treatment (SUS group), and 66 (44.9%) had MM only during treatment (DUR group). The BEF group had a higher 12-month CR rate (98.0% vs 85.7%, p = 0.017) and shorter therapeutic duration to achieve CR (4.0 vs 5.7 months, p = 0.013) than the non-MM group had. In comparison with the non-MM group, the SUS and DUR groups had a lower CR rate after 7 months of treatment (SUS vs non-MM, 37.5% vs 61.1%, p = 0.010; DUR vs non-MM 33.3% vs. 61.1%, p < 0.001), and a longer median therapeutic duration to achieve CR (SUS vs non-MM, 7.6 vs. 4.0 months, p = 0.037; DUR vs non-MM, 7.9 vs. 4.0 months, p < 0.001). Conclusion: Appearance of MM only before treatment was positively correlated with outcome of fertility-preserving treatment, while sustained MM or appearance of MM only during treatment implied poorer outcome of fertility-preserving treatment in AEH and EEC patients.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e60
Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol for a non-inferiority randomized controlled trial (SNEC trial)
Guan J, et al. J Gynecol Oncol. 2021 May;32(4):e60. https://doi.org/10.3802/jgo.2021.32.e60
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e60
Open AccessSentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol for a non-inferiority randomized controlled trial (SNEC trial)
Guan J, et al. J Gynecol Oncol. 2021 May;32(4):e60. https://doi.org/10.3802/jgo.2021.32.e60
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e57
Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
Zhou S, et al. J Gynecol Oncol. 2021 Apr;32(4):e57. https://doi.org/10.3802/jgo.2021.32.e57
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e57
Open AccessCharacteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
Zhou S, et al. J Gynecol Oncol. 2021 Apr;32(4):e57. https://doi.org/10.3802/jgo.2021.32.e57
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e13
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
Guan J, et al. J Gynecol Oncol. 2018 Aug;30:e13. https://doi.org/10.3802/jgo.2019.30.e13
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e13
Open AccessThe prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
Guan J, et al. J Gynecol Oncol. 2018 Aug;30:e13. https://doi.org/10.3802/jgo.2019.30.e13